PDF(Pubmed)
Abstract：
UNASSIGNED: Primary central nervous system lymphoma(PCNSL) is an aggressive, rare form of Non-Hodgkin lymphoma, characterized by the absence of systemic disease. There are limited data and no strictly defined guidelines for management of PCNSL.
UNASSIGNED: The aim of this study was to report a 10 year experience of PCNSL treatment, to evaluate treatment outcomes and asses Progression Free and Overall Survival of these patients.
UNASSIGNED: Study was conducted on the Haematology Clinic, Clinical center University of Sarajevo, BH, in the period from January 2012.-December 2022. Total sample of 24 patients were enrolled. All have undergone diagnostic surgery. Patients were treated with regimens based on High dose Methotrexate, with/without whole brain radiotherapy as consolidation. Treatment response was captured by imaging techniques. Patients who have relapsed were evaluated with imaging techniques and treated according to Methotrexate-based treatment protocols.
UNASSIGNED: We have captured equal gender distribution. The median age of patients was 59.5 years (range 20-79). Pathohistological analysis confirmed DLBCL diagnosis in 22 patients, T cell lymphoma and anaplastic large cell lymphoma, each in 1 patient. Chemotherapy, chemotherapy combined with WBRT and radiotherapy were given to 5, 18 and 1 patients, respectively. The overall complete response rate (CR) was 87,15%. Those receiving combined modality-treatment had higher CR than those receiving chemotherapy (94,4% versus 60%). Out of 24 patients, 11 of them relapsed. The median time to relapse was 29 months (from 1 to 105). After second line of the treatment, CR was 54,5%, while 45,45% of patients died during the treatment. 4 patients relapsed for the second time with median time to relapse of 9 months (from 2 to 77). 2 year OS rate was 67%, and the median OS rate was 45,9 months. 2 year PFS rate was 31%.
UNASSIGNED: The OS and PFS rates indicate the usage of new drugs and consolidation with autologous stem cell transplantation in patients with PCNSL in order to achieve better treatment outcomes.
UNASSIGNED: The aim of this study was to report a 10 year experience of PCNSL treatment, to evaluate treatment outcomes and asses Progression Free and Overall Survival of these patients.
UNASSIGNED: Study was conducted on the Haematology Clinic, Clinical center University of Sarajevo, BH, in the period from January 2012.-December 2022. Total sample of 24 patients were enrolled. All have undergone diagnostic surgery. Patients were treated with regimens based on High dose Methotrexate, with/without whole brain radiotherapy as consolidation. Treatment response was captured by imaging techniques. Patients who have relapsed were evaluated with imaging techniques and treated according to Methotrexate-based treatment protocols.
UNASSIGNED: We have captured equal gender distribution. The median age of patients was 59.5 years (range 20-79). Pathohistological analysis confirmed DLBCL diagnosis in 22 patients, T cell lymphoma and anaplastic large cell lymphoma, each in 1 patient. Chemotherapy, chemotherapy combined with WBRT and radiotherapy were given to 5, 18 and 1 patients, respectively. The overall complete response rate (CR) was 87,15%. Those receiving combined modality-treatment had higher CR than those receiving chemotherapy (94,4% versus 60%). Out of 24 patients, 11 of them relapsed. The median time to relapse was 29 months (from 1 to 105). After second line of the treatment, CR was 54,5%, while 45,45% of patients died during the treatment. 4 patients relapsed for the second time with median time to relapse of 9 months (from 2 to 77). 2 year OS rate was 67%, and the median OS rate was 45,9 months. 2 year PFS rate was 31%.
UNASSIGNED: The OS and PFS rates indicate the usage of new drugs and consolidation with autologous stem cell transplantation in patients with PCNSL in order to achieve better treatment outcomes.
摘要：
■原发性中枢神经系统淋巴瘤（PCNSL）是一种侵袭性，罕见的非霍奇金淋巴瘤,以不存在全身性疾病为特征。PCNSL的管理数据有限，没有严格定义的指南。
■这项研究的目的是报告PCNSL治疗10年的经验，评估这些患者的治疗结果和无进展生存期和总生存期。
■对血液诊所进行了研究，临床中心萨拉热窝大学,BH,从2012年1月起。-2022年12月。共纳入24名患者的样本。所有人都接受了诊断性手术。患者接受基于高剂量甲氨蝶呤的治疗方案，有/没有全脑放疗作为巩固。通过成像技术捕获治疗反应。使用成像技术评估复发的患者，并根据基于甲氨蝶呤的治疗方案进行治疗。
■我们注意到性别分布平等。患者的中位年龄为59.5岁（范围20-79）。病理组织学分析证实DLBCL诊断22例，T细胞淋巴瘤和间变性大细胞淋巴瘤,每人1名患者。化疗,化疗联合WBRT和放疗分别给予5、18和1例患者，分别。总体完全缓解率（CR）为87,15％。接受综合治疗的患者的CR高于接受化疗的患者（94,4％对60％）。在24名患者中，其中11人复发了。中位复发时间为29个月（1至105个月）。二线治疗后，CR为54.5%，而4545%的患者在治疗期间死亡。4例患者第二次复发，中位复发时间为9个月（从2到77）。2年OS率为67%，中位OS率为45,9个月。2年PFS率为31%。
■OS和PFS率表明在PCNSL患者中使用新药和自体干细胞移植以获得更好的治疗结果。
■这项研究的目的是报告PCNSL治疗10年的经验，评估这些患者的治疗结果和无进展生存期和总生存期。
■对血液诊所进行了研究，临床中心萨拉热窝大学,BH,从2012年1月起。-2022年12月。共纳入24名患者的样本。所有人都接受了诊断性手术。患者接受基于高剂量甲氨蝶呤的治疗方案，有/没有全脑放疗作为巩固。通过成像技术捕获治疗反应。使用成像技术评估复发的患者，并根据基于甲氨蝶呤的治疗方案进行治疗。
■我们注意到性别分布平等。患者的中位年龄为59.5岁（范围20-79）。病理组织学分析证实DLBCL诊断22例，T细胞淋巴瘤和间变性大细胞淋巴瘤,每人1名患者。化疗,化疗联合WBRT和放疗分别给予5、18和1例患者，分别。总体完全缓解率（CR）为87,15％。接受综合治疗的患者的CR高于接受化疗的患者（94,4％对60％）。在24名患者中，其中11人复发了。中位复发时间为29个月（1至105个月）。二线治疗后，CR为54.5%，而4545%的患者在治疗期间死亡。4例患者第二次复发，中位复发时间为9个月（从2到77）。2年OS率为67%，中位OS率为45,9个月。2年PFS率为31%。
■OS和PFS率表明在PCNSL患者中使用新药和自体干细胞移植以获得更好的治疗结果。
